Evidence map›Paper›PMID 35073214›Full record

ArticleInternational journal of radiation biology2022

Ioanna Liatsou, Jing Yu, Remco Bastiaannet, Zhi Li, Robert F Hobbs, Julien Torgue, George Sgouros

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of radiation biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Efficacy of HER2-Targeted IntraperitonealJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  4. Article
  5. Dosimetry of [Molecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Ioanna LiatsouDepartment of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0003-3423-6401
Jing YuDepartment of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Remco BastiaannetDepartment of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Zhi LiDepartment of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Robert F HobbsDepartment of Radiation Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Julien TorgueORANO Med, Plano, TX, USA.
George SgourosDepartment of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

Funding

Dose-Response in Radionuclide TherapyR01CA116477 · NCI · JOHNS HOPKINS UNIVERSITY · PI HOBBS, ROBERT FRANCOIS, SGOUROS, GEORGE · 2006 to 2022
$7.1M
NCI NIH HHS R01 CA116477
6 · The paper itself

Abstract

purposeIn the current work, the RBE of a MATERIALS AND

methodsMammary carcinoma NT2.5 cells were treated with (0-3.70) kBq/ml of radiolabeled antibody. Nonspecific binding was assessed with addition of excess amount of unlabeled antibody. The colony formation curves were converted from activity concentration to cell nucleus absorbed dose by simulating the decay and transport of all daughter and secondary particles of

resultsThe radiolabeled antibody yielded an RBE of 8.3 at 37% survival and a survival independent RBE (i.e. RBE2) of 9.9. Unbound/untargeted

Indexed as

CarcinomaLeadAlpha ParticlesAnimalsCell LineDose-Response Relationship, RadiationMiceRatsRelative Biological EffectivenessLeadAlpha particleLET radiationradiosensitivityRBE

Identifiers

PMID35073214
PMCPMC9673603

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.